Biotech B8 of 9 ~35 min B1, B3 required · BP2 helpful

The Biotech Industry

Moderna was founded in 2010 with $40M and a speculative bet on mRNA. By 2022 it had $36B in revenue. This module is how the industry — risk, capital, failure, and occasional vindication — actually works.

Hook

In December 2010, Moderna Therapeutics was founded with $40 million in venture capital and a single platform: mRNA. The science was speculative, untested in humans, and had been pursued without commercial success by other companies for over a decade. Most pharmaceutical observers considered Moderna's pitch unrealistic.

In November 2020 — ten years later — Moderna's mRNA COVID-19 vaccine demonstrated 94.5% efficacy in Phase III clinical trials. The company's market valuation surged from approximately $7 billion to over $100 billion at peak. By 2022, Moderna had generated over $36 billion in revenue, mostly from a single product.

This is the biotech industry in compressed form: enormous risk, decade-plus timelines, technological skepticism, sudden vindication, extraordinary financial outcomes. Most biotech startups don't have stories like Moderna's — most fail. But the possibility of stories like Moderna's is what makes biotech an industry at all.

The Structure of the Biotech Industry

The structure of the biotech industryA pyramid of three therapeutic tiers: Big Pharma at the top with tens of billions in revenue, mid-sized platform-built biotech in the middle, and thousands of small startups at the base where fewer than 10 percent ever ship a product, with an arrow showing startups acquired upward. On the right, support sectors that serve the whole industry: tools and services, CROs that run trials, diagnostics, and ag-biotech, often more profitable because they sell to everyone. The structure is fluid; several companies climbed from startup to Big Pharma scale.How the biotech industry is layered — and how companies move between layersBig PharmaPfizer, Roche, Novartis, Merck — $10s of billionsMid-sized biotechModerna, Regeneron, Vertex — platform-builtSmall startupsthousands; <10% ever ship a productstartups get acquired upwardServing the whole industryTools & services (Thermo Fisher, Illumina)CROs — run trials (IQVIA, ICON)Diagnostics (LabCorp, Foundation)Ag-biotech (Bayer, Corteva, Syngenta)Often more profitable than drug makers —they sell to everyone, regardless of which drug wins.The structure is fluid: Gilead, Amgen, Vertex, and Regeneron all climbed from startup to Big-Pharma scale.

The biotech industry has a distinct layered structure. Big Pharma (Pfizer, Roche, Novartis, J&J, Merck, AbbVie, Sanofi, AstraZeneca) have annual revenues of tens of billions and significant biotech capabilities acquired through internal development and M&A. Mid-sized biotech (Moderna, Regeneron, Vertex, Biogen, Gilead, Alnylam, Illumina) are large enough to be independent but smaller than Big Pharma — often founded around a specific platform technology like mRNA, antibody discovery, or gene editing.

Small biotech startups — thousands of companies, usually founded by academics and VCs around specific scientific breakthroughs. Most have no products on the market. By some estimates, fewer than 10% of biotech startups produce a commercial product. Service and tools companies (Thermo Fisher, Danaher, Lonza, Charles River) are often more profitable than therapeutic companies because they serve the whole industry regardless of which specific drugs succeed.

The structure is dynamic. Small startups get acquired by mid-sized companies; mid-sized companies get acquired by Big Pharma. Occasionally mid-sized biotech companies grow to become Big Pharma equivalents — Gilead, Amgen, Vertex, and Regeneron have all made this transition over the past decade.

Venture Capital and Funding the Pipeline

The biotech funding pipeline and cash burnA cash curve over the financing stages. It starts at zero at seed, dips progressively negative through Series A preclinical, Series B to D clinical trials, reaching the deepest point a valley of death during trials, then recovers through IPO, approval and first revenue, and finally M&A or profit. Total private funding before IPO can reach 200 million to 1 billion dollars, the whole arc runs 10 to 15 years, and most companies never reach profit.Funding the pipeline: years of burning cash before any revenue$0seed$0.1–5MSeries ApreclinicalSeries B–Dclinical trialsIPOpublic marketsapprovalfirst revenueM&A / profit“valley of death” — deepest cash burnPrivate funding before IPO can hit $200M–$1B; the arc runs 10–15 years — most companies never reach profit.

Bringing a single drug to market costs roughly $1–2 billion and takes 10–15 years. Seed and angel funding ($100K–$5M) validates scientific concepts. Series A through later rounds advance progressively — Series A for early preclinical, Series B–D for clinical trials. Total private funding before IPO can reach $200M–$1B.

Major biotech VCs: Flagship Pioneering (founded Moderna), ARCH Venture Partners, OrbiMed, Third Rock Ventures, Atlas Venture, F-Prime Capital. These firms employ scientific staff with deep domain expertise. Partnerships and licensing with larger pharma companies provide upfront payments, milestone payments, and royalties. M&A: AbbVie acquired Allergan for $63B; Pfizer acquired Seagen for $43B.

Government funding — NIH grants (~$45B annually), NSF, BARDA contracts — provides substantial early-stage research support. The biotech financing system is fragile: investor sentiment changes rapidly. Many companies that looked promising in 2020–2021 closed or were heavily restructured by 2023–2024. Career stability in biotech is consequently lower than in many other technical industries.

Intellectual Property: Patents, Trade Secrets, and Bayh-Dole

The NIH paradoxA circular flow of four nodes. NIH funding of about 45 billion dollars a year in public money leads to academic discovery, the foundational science behind over 90 percent of new drugs. That leads to private commercialization where startups and Big Pharma develop and sell the products. Those are then sold back to the public via Medicare and Medicaid at market prices, completing the loop. Reforms such as reasonable-pricing clauses and Bayh-Dole march-in rights exist on paper but are almost never used.The NIH paradox: public science, private profit, public priceNIH funding~$45B/yr public moneyAcademic discoveryfoundational science; 90%+of new drugsPrivate commercializationstartups + Big Pharmadevelop & sellSold back to publicvia Medicare/Medicaid atmarket pricesReforms (reasonable-pricing clauses, Bayh-Dole march-in rights) exist on paper but are almost never used.

The biotech business model rests on IP protection. Biotech patents cover: compositions of matter (specific molecules, antibodies, cell lines), methods of use (using compound X to treat disease Y), methods of production, and devices. Patents last 20 years from filing; the Hatch-Waxman Act provides up to 5 years of extension for regulatory delays.

Patent thickets: many biotech products are covered by dozens or hundreds of overlapping patents. CRISPR commercialization is the famous example — the landscape is so complex that companies pursuing CRISPR therapies must license from multiple competing patent holders. Trade secrets — manufacturing processes, cell lines, proprietary algorithms — are kept confidential rather than disclosed in patents. Potentially perpetual protection, but not protected against independent discovery.

The Bayh-Dole Act (1980) allowed universities to retain patent rights to inventions made with federal funding. Before it, federally funded inventions were generally placed in the public domain. After it, universities could patent academic inventions and license them to companies — including startup companies founded specifically to commercialize academic research. Critics argue that publicly funded inventions then sold back to the public at high prices represent a problematic public-private value transfer.

Drug Development Economics and Careers

The drug development attrition funnelA shrinking funnel over 10 to 15 years. Discovery starts with about 10,000 compounds. Preclinical narrows to about 250 entering testing. Phase I has about 5 reaching humans. Phase II to III leaves few surviving trials. FDA approval yields about 1 drug. The roughly 10,000 starting compounds become one approved drug; the failures are paid for by the winners, which is why prices are high.Why a drug costs $1–2B: the attrition funnel over 10–15 yearsDiscovery~10,000 compoundsPreclinical~250 enter testingPhase I~5 reach humansPhase II–IIIfew survive trialsFDA approval~1 drug~10,000 starting compounds → one approved drug. The failures are paid for by the winners — hence high prices.

The drug development funnel is famously leaky. For every 5,000–10,000 compounds entering preclinical development, roughly 5 enter clinical trials, and only about 1 eventually reaches approval. Most drugs fail in clinical trials. Even at Phase III, failure rates are high — especially for cancer and CNS drugs. The $1–2 billion average cost includes all the failures.

Career paths in biotech span a wide range: research associate (BS/MS entry-level), research scientist (PhD), clinical research associate (CRA), regulatory affairs specialist, medical affairs (MD), business development, IP/biotech law, venture capital (often PhD + MBA), and computational/data science roles that have grown enormously with the rise of genomics and AI-driven drug discovery.

Multiple entry points exist for different skill combinations. What matters more than the specific degree is deep domain knowledge combined with the ability to communicate across disciplines — scientists who understand business, lawyers who understand the science, business people who understand the regulatory landscape. The industry is interdisciplinary in practice even when it doesn't always advertise that way.

Wait, Actually…

The most successful biotech investor of all time isn't a venture capitalist or a Wall Street firm. It's the United States National Institutes of Health.

NIH provides approximately $45 billion annually in research funding. A 2018 study in PNAS found that over 90% of the drugs approved between 2010 and 2016 had received some NIH research funding before approval. The economic return is enormous — pharmaceutical revenues exceed $1 trillion globally — but the returns flow primarily to private companies and shareholders, not back to taxpayers. And then the same drugs are sold back to taxpayers through Medicare and Medicaid at prices set by the private companies.

Proposed reforms include reasonable pricing clauses in NIH grants, march-in rights under Bayh-Dole (theoretically allowing the government to license patents to others if products aren't reasonably available — almost never used), and public manufacturing options. None have gained substantial political traction. The current system — public funding for foundational research, private commercialization, market-based pricing — is deeply entrenched. Whether it's the right balance is one of the larger unresolved questions in biotech and pharmaceutical policy.

Check Your Understanding

Why is biotech an unusually capital-intensive industry?

  • Biotech companies pay extremely high salaries
  • Bringing a drug to market typically costs $1–2 billion and takes 10–15 years, mostly before any revenue
  • Biotech requires expensive office space
  • Biotech companies are required to have large insurance policies

What is the major significance of the Bayh-Dole Act (1980)?

  • It established the FDA
  • It allowed universities to retain patent rights to inventions made with federal funding, enabling academic-industry technology transfer
  • It created the venture capital industry
  • It banned compulsory licensing

Which of the following is generally NOT a typical entry path into biotech?

  • Research associate after undergraduate biology degree
  • Research scientist after PhD program
  • Medical affairs role after MD
  • Direct executive hire from unrelated industry without prior biotech experience

What is unusual about NIH's role in pharmaceutical innovation?

  • NIH directly manufactures and sells drugs
  • NIH-funded research underlies the vast majority of FDA-approved drugs, but commercialization profits flow primarily to private companies
  • NIH has no role in pharmaceutical research
  • NIH only funds basic biology research
Mini-Project

Build a Biotech Industry Profile

Pick one specific subsector and build a market profile. Suggestions: mRNA therapeutics (Moderna, BioNTech, CureVac, Arcturus), CAR-T cell therapy (Kite/Gilead, Novartis, Bristol Myers Squibb), cultivated meat (UPSIDE Foods, GOOD Meat, Mosa Meat), DNA sequencing platforms (Illumina, Pacific Biosciences, Oxford Nanopore), or synthetic biology platforms (Ginkgo Bioworks, Twist Bioscience).

Document: (1) the technology and market opportunity, (2) major companies with relative sizes and key products, (3) recent major events (IPOs, acquisitions, clinical results), (4) competitive landscape, (5) major risks and uncertainties, (6) investment thesis, (7) one contrarian view running counter to mainstream sentiment. This is the work of a biotech equity analyst. Understanding one subsector deeply lets you apply the same framework to any other.

Where this takes you
B9Capstone — synthesize everything from this trackPolicyAll eight policy modules apply to how this industry is regulatedGenomicsThe basic science this industry monetizesMarine BioAnother industry context powered by the same foundational science